Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 110

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 110
---
 an estimated 280 million people
worldwide including 21.0 million individuals in the United States develop a major depressive episode within a given year. We estimate
that there are 69 million depression patients in India, 71 million in China, 37 million in Europe, and 6 million in Japan. MDD is one
of the most prevalent mental illnesses across all demographics. According to the Clinical Psychology Review, MDD follows a chronic course
of repeated bouts of remission and recurrence in about 50% of people affected. The chronic nature of MDD makes it the leading cause of
years lost to disability in the world, and MDD patients are more likely to commit suicide. According to the American Journal of Psychiatry,
roughly 2% of MDD patients treated as outpatients, and 4% of those hospitalized because of their condition, commit suicide. In addition,
studies suggest that some patients exhibit a higher mortality rate even after controlling for suicide. Due to the prevalence and severity
of MDD, the treatment of the disorder is a pressing concern for mental health professionals.

We focus on the population segment for whom conventional
treatment (medicinal and/or psychotherapy) of MDD has not provided the required clinical response, as patients who are treatment-resistant
are entitled to reimbursement for Deep TMS treatment. It is customary to assess that approximately half of the sufferers from the illness
do not respond to the first medicinal treatment, and that one-third do not find conventional solutions to their suffering at all. In addition,
even among patients who receive medicinal treatment that is found effective, many suffer from severe side effects that cause them to abandon
the treatment and be left with their depressive condition. We aim to meet the enormous need of these groups of treatment-resistant patients
and provide effective, non-medicinal treatment which is not accompanied by the systemic side effects of the medication on the one hand
and the electroconvulsive therapy (ECT) treatments on the other hand (such as damage to memory).

Treatment
Options for MDD

Treatment for patients diagnosed with MDD varies
by disease severity. For patients with mild to moderate depression, first line treatment is usually psychotherapy (the treatment of mental
disorders by psychological means), especially if the patient is able to identify particular stressors or sources of depressive symptoms.
For some of these patients, pharmacotherapy (anti-depressant medication) may be used to supplement psychotherapy. For patients with moderate
depression, pharmacotherapy with or without psychotherapy